Source-grounded facts extracted from TREACE MEDICAL CONCEPTS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TREACE MEDICAL CONCEPTS, INC. shareholders approved Ratification of appointment of Grant Thornton LLP as independent registered public accounting firm at the 2026-05-19 meeting.
“By the vote stated below, the stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Vote 47,885,305 120,733 135,524 0”
TREACE MEDICAL CONCEPTS, INC. shareholders approved Advisory vote on executive compensation at the 2026-05-19 meeting.
“By the vote stated below, the stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers: For Against Abstain Broker Non-Vote 32,785,505 1,724,383 115,242 13,516,432”
TREACE MEDICAL CONCEPTS, INC. shareholders approved Election of three Class II directors at the 2026-05-19 meeting.
“The stockholders elected, by the votes indicated below, the following nominees to the Company’s Board of Directors to serve as Class II directors for a three-year term of office expiring at the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified: Name For Withheld Broker Non-Vote Lance A. Berry 33,804,407 820,723 13,516,432 Elizabeth S. Hanna 30,856,965 3,768,165 13,516,432 Jane E. Kiernan 33,587,226 1,037,904 13,516,432”
TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2026 results: revenue $47.2 million, net income $(18.0) million, EPS $(0.28) per share. Guidance reaffirmed.
“treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. • Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the”
TREACE MEDICAL CONCEPTS, INC. incurred revolving credit of $30 million with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL at 3-Month SOFR plus 4.00% maturing 60 month.
“The Revolving Loan Agreement establishes a 60 month revolving loan facility providing $30 million in additional borrowing capacity to the Company.”
TREACE MEDICAL CONCEPTS, INC. incurred term loan of up to $125 million with SLR Investment Corp. at 1-Month SOFR plus 5.05% maturing 60 month.
“The Term Loan Agreement provides a 60 month term loan facility for up to $125 million in borrowing capacity to the Company over four tranches. At the loan closing, the Company drew $60 million under tranche one.”
John T. Treace was appointed as Chairman of the Board at TREACE MEDICAL CONCEPTS, INC..
“appoint John T. Treace to serve as Chairman of the Board, effective upon the expiration of James T. Treace’s current term at the Company’s 2025 Annual Meeting.”
James T. Treace retired as Director at TREACE MEDICAL CONCEPTS, INC..
“his intent to retire from the Board at the expiration of his current term at the 2025 annual meeting of stockholders”
TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2024 results: revenue $51.1 million, net income ($18.7) million, EPS ($0.30) per share. Guidance lowered.
“through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023 • Gross margin of 80.2% in first quarter 2024 • First quarter 2024 net loss attributable to common stockholders was”
TREACE MEDICAL CONCEPTS, INC. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).
“On February 27, 2024, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and year ended December 31, 2023.”
TREACE MEDICAL CONCEPTS, INC. reported the full-year 2023 results: revenue $186.7 million to $187.1 million.
“Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023”
TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter of 2023 results: revenue $61.8 million to $62.2 million.
“Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023”
TREACE MEDICAL CONCEPTS, INC. reported third quarter ended September 30, 2023 results: revenue $40.8 million, net income ($17.5) million, or ($0.28) per share, EPS ($0.28) per share. Guidance lowered.
“through its Lapiplasty ® 3D Bunion Correction ® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: • Revenue of $40.8 million in the third quarter, a 23% increase over same period last year and a 36% increase year to date over prior year • Blended average revenue per Lapiplasty ® procedure kit sold was”
TREACE MEDICAL CONCEPTS, INC. reported full-year 2023 results: revenue $191 million to $197 million. Guidance raised.
“Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company’s 2022 revenue.”
TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.
“Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last year”
TREACE MEDICAL CONCEPTS, INC. completed an acquisition involving MIOS Marketing, LLC d/b/a RedPoint Medical3d ("RPM-3D") for $20.0 million (closed 2023-06-12).
“of RPM-3D. On June 12, 2023, the Company completed its acquisition of certain assets of RPM-3D pursuant to the APA. In accordance with the APA, at closing, TMCI paid RPM-3D $20.0 million in exchange for RPM-3D’s assets used in providing pre-operative planning and patient-specific guides for the surgical correction of foot and ankle deformities. Under the APA,”
TREACE MEDICAL CONCEPTS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-23 meeting.
“The stockholders ratified, by the votes indicated below, the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
TREACE MEDICAL CONCEPTS, INC. shareholders approved Election of Class I Directors at the 2023-05-23 meeting.
“The stockholders elected, by the votes indicated below, the following nominees to the Company’s Board of Directors to serve as Class I directors for a three-year term of office expiring at the 2025 annual meeting of the stockholders or until their respective successors have been duly elected and qualified:”
TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2023 results: revenue $42.2 million, net income ($13.5) million, EPS ($0.23) per share. Guidance raised.
“First Quarter 2023 Financial Results Revenue for the first quarter of 2023 was $42.2 million, representing an increase of 45% compared to $29.0 million in the first quarter of 2022. The increase was driven by an increased number of Lapiplasty® procedure kits sold as a result of an expanded surgeon customer base and increased blended average selling prices due to increased adoption of our newer technologies and expanding product line. Gross profit for the first quarter of 2023 was $34.2 million, representing an increase of 43% compared to a gross profit of $23.9 million in the first quarter of 2022. Gross margin totaled 80.9% in the first quarter of 2023, compared to 82.3% in the first quarter of 2022. The decrease was primarily due to an increase in payroll costs and an increase in inventory and obsolescence provisions. ___________________ 1 The ACFAS Scientific Poster, which includes additional details such as patient demographics, inclusion/exclusion criteria, and complications repor”
TREACE MEDICAL CONCEPTS, INC. reported the year ended December 31, 2022 results: revenue $141.8 million, net income ($42.8) million, or ($0.77) per share, EPS ($0.77) per share.
“Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. • Blended average revenue per Lapiplasty® procedure kit sold was $5,907, a 10% increase over the same period last year and a 2% increase sequentially.”
TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $49.8 million, net income ($4.4) million, or ($0.08) per share, EPS ($0.08) per share.
“of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. •”
Thomas Timbie departed as Director at TREACE MEDICAL CONCEPTS, INC..
“On February 16, 2023, F. Barry Bays and Thomas Timbie provided notice to the board of directors (the “ Board ”) of Treace Medical Concepts, Inc. (the “ Company ”) of their intent to retire from the Board at the expiration of their current terms at the 2023 annual meeting of stockholders (the “ 2023 Annual Meeting ”) and not to stand for re-election.”
F. Barry Bays departed as Director at TREACE MEDICAL CONCEPTS, INC..
“On February 16, 2023, F. Barry Bays and Thomas Timbie provided notice to the board of directors (the “ Board ”) of Treace Medical Concepts, Inc. (the “ Company ”) of their intent to retire from the Board at the expiration of their current terms at the 2023 annual meeting of stockholders (the “ 2023 Annual Meeting ”) and not to stand for re-election.”
TREACE MEDICAL CONCEPTS, INC. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC valued at Issuance and sale of 4,761,905 shares of common stock at $21.00 per share to public, underwriters pu (effective 2023-02-07).
“On February 7, 2023, Treace Medical Concepts, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 4,761,905 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (“Common Stock”), to the Underwriters (the “Offering”).”
TREACE MEDICAL CONCEPTS, INC. reported fourth quarter and full year 2022 results: revenue $49.1 to $49.6 million and $141.2 to $141.7 million, respectively.
“preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively. The full”
TREACE MEDICAL CONCEPTS, INC. reported quarter ended September 30, 2022 results: revenue $33.1 million, net income ($12.1) million, EPS ($0.22) per share. Guidance raised.
“Third Quarter 2022 Financial Results Revenue for the third quarter of 2022 was $33.1 million, representing an increase of 53% compared to $21.6 million in the third quarter of 2021. The increase was driven by an increased number of Lapiplasty® procedure kits sold as a result of an expanded surgeon customer base and increased blended average selling prices due to increased adoption of our newer technologies and expanding product line. Gross profit for the third quarter of 2022 was $26.4 million, representing an increase of 52% compared to a gross profit of $17.4 million in the third quarter of 2021. Gross margin decreased to 80.0% in the third quarter of 2022, compared to 80.4% in the third quarter of 2021. The decrease in gross margin was primarily due to an increase in allocations of payroll and related expenses and an increase in capitalized surgical instrument depreciation, which were partially offset by a decrease in royalty expense in relation to products sold in the quarter and l”
Jane E. Kiernan was appointed as Director at TREACE MEDICAL CONCEPTS, INC..
“On September 27, 2022, Treace Medical Concepts, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has, based on the recommendation of the Board’s Nominating, Compliance and Governance Committee, appointed Lance A. Berry and Jane E. Kiernan to the Company’s Board effective October 1, 2022.”
Lance A. Berry was appointed as Director at TREACE MEDICAL CONCEPTS, INC..
“On September 27, 2022, Treace Medical Concepts, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has, based on the recommendation of the Board’s Nominating, Compliance and Governance Committee, appointed Lance A. Berry and Jane E. Kiernan to the Company’s Board effective October 1, 2022.”
John R. Treace departed as director at TREACE MEDICAL CONCEPTS, INC..
“On February 22, 2022, John R. Treace provided notice to the board of directors (the “ Board ”) of Treace Medical Concepts, Inc. (the “ Company ”) of his intent to retire from the Board at the expiration of his current term at the 2022 annual meeting of stockholders (the “ 2022 Annual Meeting ”) and not to stand for re-election.”
Deepti Jain was appointed as director at TREACE MEDICAL CONCEPTS, INC..
“appointed Betsy Hanna and Deepti Jain to the Company’s Board effective October 1, 2021.”
Betsy Hanna was appointed as director at TREACE MEDICAL CONCEPTS, INC..
“appointed Betsy Hanna and Deepti Jain to the Company’s Board effective October 1, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.